United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News Urovant Sciences acquires licensing for hMaxi-K gene therapy to treat overactive bladder from Ion Channel Urovant Sciences has secured global licensing rights from Ion Channel Innovations for the development and commercialization of a… bypharmanewsdailyAugust 29, 2018
